Company:  EVOFEM BIOSCIENCES, INC. (EVFM)
Form Type:  SC 13G/A
Filing Date:  7/12/2021 
CIK:  0001618835 
Address:  12400 HIGH BLUFF DRIVE
SUITE 600
 
City, State, Zip:  SAN DIEGO, California 92130 
Telephone:  (858) 550-1900 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.71  
Change: 
0.0131 (1.89%)  
Trade Time: 
Oct 18  
Market Cap: 
$121.34M
Trade EVFM now with 

© 2021  
Description of Business
We are a San Diego-based commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. Our first commercial product, Phexxi vaginal gel, was approved by the FDA on May 22, 2020 and commercially launched in the United States in September 2020. Phexxi is the first and only FDA-approved hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Our strategy is to commercialize Phexxi in the United States ourselves and in all other global markets through partnerships. Our lead product candidate EVO100 is being evaluated in women for the prevention of chlamydia and gonorrhea - two of the most pervasive sexually transmitted infections (STIs) in the United States. Currently, there are no FDA-approved prescription products to prevent infection by either of these common and dangerous pathogens.
Register and access this filing in:     
  FORM SC 13G/A